Long-term follow-up analysis of 100 patients with splenic marginal zone lymphoma treated with splenectomy as first-line treatment
Authors:
- Catherine TraulléCTCatherine Traullé
- Nicolas MounierNMNicolas Mounier
- Claire BenetCBClaire Benet
- Nicolas Munoz-BongrandNMNicolas Munoz-Bongrand
- Sandy AmorinSASandy Amorin
- Maria-Elena NogueraMNMaria-Elena Noguera
- Alexandra Traverse-GlehenATAlexandra Traverse-Glehen
- Martine FfrenchMFMartine Ffrench
- Lucile BaseggioLBLucile Baseggio
- Pascale FelmanPFPascale Felman
- Evelyne Callet-BauchuECEvelyne Callet-Bauchu
- 7 March 2014
- journal article
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 55 (8) , 1854-1860
Abstract
Splenectomy is considered as one of the first-line treatments for symptomatic patients with splenic marginal zone lymphoma (SMZL). Between 1997 and 2012, 100 hepatitis C virus-negative patients with SMZL were treated by splenectomy as first-line treatment. At 6 months, all patients but three recovered from all cytopenias. The median lymphocyte count at 6 months and 1 year was 11.51 × 10(9)/L and 6.9 × 10(9)/L, respectively. Median progression-free survival (PFS) was 8.25 years. The 5-year and 10-year overall survival (OS) rates were 84% and 67%, respectively. Histological transformation occurred in 11% of patients, and was the only parameter significantly associated with a shorter time to progression (p = 0.0001). Significant prognostic factors for OS were age (p = 0.0356) and histological transformation (p = 0.0312). In this large retrospective cohort, we confirmed that splenectomy as first-line treatment in patients with SMZL corrected cytopenias and lymphocytosis within the first year and was associated with a good PFS.Keywords
This publication has 35 references indexed in Scilit:
- Rituximab, used alone or in combination, is superior to other treatment modalities in splenic marginal zone lymphomaBritish Journal of Haematology, 2012
- Whole-genome sequencing identifies recurrent somatic NOTCH2 mutations in splenic marginal zone lymphomaJournal of Experimental Medicine, 2012
- The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone developmentJournal of Experimental Medicine, 2012
- Post-splenectomy and hyposplenic statesThe Lancet, 2011
- Stereotyped patterns of B-cell receptor in splenic marginal zone lymphomaHaematologica, 2010
- Significant efficacy of 2-CdA with or without rituximab in the treatment of splenic marginal zone lymphoma (SMZL)Annals of Oncology, 2009
- Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteriaLeukemia, 2007
- Revised Response Criteria for Malignant LymphomaJournal of Clinical Oncology, 2007
- Deoxycoformycin (pentostatin) in the treatment of splenic marginal zone lymphoma (SMZL) with or without villous lymphocytesEuropean Journal of Haematology, 2005
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958